Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etoposide Phosphate

FDA-approved product (injectable, injection), marketed as Etopophos Preservative Free.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Etoposide Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lung cancer
  • Lung neoplasm
  • Neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Podophyllotoxin derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etoposide Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etoposide Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

    NCT00499616 · start 2007-10-08

    Registered record
    Registry ID
    NCT00499616
    Conditions
    Neuroblastoma
    Interventions
    carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; topotecan hydrochloride; Isotretinoin; Surgery; Filgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-10-08
    Completion
    2021-06-30
    Enrolment
    464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    Interventioncarboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide +4 more
    PhasePhase 3
    Registry statusCompleted

  • Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

    NCT00504751 · start 2007-05

    Registered record
    Registry ID
    NCT00504751
    Conditions
    Non-Hodgkin's Lymphoma
    Interventions
    bortezomib, dexamethasone, ifosfamide; mesna, cisplatin, etoposide, rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2012-02-17
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin's Lymphoma
    Interventionbortezomib, dexamethasone, ifosfamide; mesna, cisplatin, etoposide, rituximab
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

    NCT00526318 · start 2007-01

    Registered record
    Registry ID
    NCT00526318
    Conditions
    Neuroblastoma
    Interventions
    filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; iobenguane I 131; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2007-01
    Completion
    Not recorded
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    Interventionfilgrastim; carboplatin; cisplatin; cyclophosphamide +12 more
    PhaseNot applicable
    Registry statusUnknown

  • UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

    NCT00574080 · start 2006-07

    Registered record
    Registry ID
    NCT00574080
    Conditions
    Multiple Myeloma
    Interventions
    Interim/Maintenance Dexamethasone; Induction/Consolidation Dexamethasone; Induction/Consolidation Cisplatin; Induction/Consolidation Adriamycin; InductionConsolidation Cyclophosphamide; Induction/Consolidation Etoposide; Induction Pegfilgrastim; Transplant 1 Dexamethasone; Transplant 1 Cisplatin; Transplant 1 Adriamycin; Transplant 1 Cyclophosphamide; Transplant 1 Etoposide; Transplant 1 Melphalan; Transplant 1 and 2 Pegfilgrastim; Autologous Peripheral Blood Stem Cell Transplant (ASCT); Transplant 2 Carmustine; Transplant 2 Etoposide; Transplant 2 Cytarabine; Transplant 2 Melphalan; Transplant 2 Dexamethasone; Transplant 1 and 2 Bortezomib; Transplant 1 and 2 Thalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-07
    Completion
    2011-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionInterim/Maintenance Dexamethasone; Induction/Consolidation Dexamethasone; Induction/Consolidation Cisplatin; Induction/Consolidation Adriamycin +18 more
    PhasePhase 3
    Registry statusTerminated

  • Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

    NCT00477035 · start 2006-05

    Registered record
    Registry ID
    NCT00477035
    Conditions
    Leukemia; Multiple Myeloma
    Interventions
    CIK cells; etoposide; bcnu; cyclophosphamide; gemcitabine; vinorelbine; melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-05
    Completion
    2011-03
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Multiple Myeloma
    InterventionCIK cells; etoposide; bcnu; cyclophosphamide +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

    NCT00315705 · start 2006-03

    Registered record
    Registry ID
    NCT00315705
    Conditions
    Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed Leukemia
    Interventions
    clofarabine; Etoposide; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    2010-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed Leukemia
    Interventionclofarabine; Etoposide; Cyclophosphamide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

    NCT00392886 · start 2004-03

    Registered record
    Registry ID
    NCT00392886
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    carboplatin; cisplatin; cyclophosphamide; etoposide; methotrexate; temozolomide; thiotepa; vincristine sulfate; autologous bone marrow transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-03
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventioncarboplatin; cisplatin; cyclophosphamide; etoposide +8 more
    PhasePhase 3
    Registry statusUnknown

  • Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

    NCT00505921 · start 2003-03

    Registered record
    Registry ID
    NCT00505921
    Conditions
    Lymphoma
    Interventions
    Campath-1H; G-CSF; GM-CSF; BCNU; Stem Cell Transplant; Preparative Regimen for Allogenic Stem Cell Transplantation; Cytarabine; Etoposide; Melphalan; Campath; Fludarabine; Cyclophosphamide; Low dose total body irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-03
    Completion
    2009-11
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionCampath-1H; G-CSF; GM-CSF; BCNU +9 more
    PhasePhase 2
    Registry statusTerminated

  • Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

    NCT00043979 · start 2002-09-19

    Registered record
    Registry ID
    NCT00043979
    Conditions
    Sarcoma
    Interventions
    F-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; doxorubicin hydrochloride; etoposide; fludarabine phosphate; melphalan; prednisone; sirolimus; tacrolimus; vincristine sulfate; peripheral blood stem cell transplantation; Filgrastim; Peripheral Blood Stem Cell donation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09-19
    Completion
    2011-12-14
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionF-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine +11 more
    PhasePhase 2
    Registry statusCompleted

  • Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma

    NCT00366275 · start 2002-01

    Registered record
    Registry ID
    NCT00366275
    Conditions
    Follicular Lymphoma
    Interventions
    Immunochemotherapy, in vivo purging and autrotransplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2007-09
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionImmunochemotherapy, in vivo purging and autrotransplant
    PhasePhase 2
    Registry statusCompleted

  • Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

    NCT00006184 · start 2001-02-08

    Registered record
    Registry ID
    NCT00006184
    Conditions
    Multiple Myeloma
    Interventions
    Myeloma Immunoglobulin Idiotype Vaccine; Bortezomib; Cyclophosphamide; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine Sulfate; Methotrexate; GMCSF (granulocyte macrophage colony stimulating factor); GCSF (granulocyte colony stimulating factor)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-02-08
    Completion
    2008-01-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionMyeloma Immunoglobulin Idiotype Vaccine; Bortezomib; Cyclophosphamide; Cyclosporine +8 more
    PhasePhase 2
    Registry statusCompleted

  • Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

    NCT00005985 · start 2000-08

    Registered record
    Registry ID
    NCT00005985
    Conditions
    Lymphoma
    Interventions
    filgrastim; carmustine; cyclophosphamide; cytarabine; dexamethasone; etoposide; mitoxantrone hydrochloride; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-08
    Completion
    2007-02
    Enrolment
    213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; carmustine; cyclophosphamide; cytarabine +5 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Etoposide in Breast Cancer Patients

    NCT00026949 · start 1999-08

    Registered record
    Registry ID
    NCT00026949
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1999-08
    Completion
    2004-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

    NCT00003621 · start 1999-02

    Registered record
    Registry ID
    NCT00003621
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    carmustine; cisplatin; etoposide; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-02
    Completion
    2005-07
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventioncarmustine; cisplatin; etoposide; radiation therapy
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

    NCT00049439 · start 1998-03

    Registered record
    Registry ID
    NCT00049439
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; etoposide; lomustine; procarbazine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-03
    Completion
    2008-02
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; etoposide; lomustine +1 more
    PhasePhase 2
    Registry statusCompleted